Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Current Prodrug Design for Drug Discovery

Author(s): Pei-Wen Hsieh, Chi-Feng Hung and Jia-You Fang

Volume 15, Issue 19, 2009

Page: [2236 - 2250] Pages: 15

DOI: 10.2174/138161209788682523

Price: $65

Abstract

Prodrugs are inactive compounds which are metabolized either chemically or enzymatically in a controlled or predictable manner to the parent active drug inside the body. Prodrugs can enhance the therapeutic efficacy and/or reduce adverse effects via different mechanisms, including increased solubility, improved permeability and bioavailability, prolonged half-life, and tissue-targeted delivery. Besides the prodrug itself, optimization of vehicles and other enhancement techniques is important as well. Strategies to improve the oral bioavailability and achieve tumor-specific targeting have been the most important developments in prodrug design during the last 5 years. This review describes recent developments in orally administered and tumor-targeted prodrugs. Pharmacokinetic and pharmacodynamic evaluations of these prodrugs are systematically introduced in this review.

Keywords: Prodrug, oral administration, anticancer drug, pharmacokinetics, pharmacodynamics


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy